In Vivo Leukemia Models: How Xenografts Are Changing Preclinical Oncology
In vivo xenograft models, where human leukemia cells are implanted into immunocompromised mice, have become indispensable tools in preclinical oncology research. These models offer a physiologically relevant environment to study tumor biology, drug efficacy, and resistance mechanisms in ways that in vitro cultures cannot replicate.
Leukemia xenografts can be established using either subcutaneous implantation, which allows tumor growth as solid masses, or systemic injection (often intravenous), which better mimics disseminated leukemia in the bone marrow and peripheral blood. Both approaches provide unique insights: subcutaneous models facilitate tumor volume measurement and histological analysis, while systemic models reflect disease progression and metastasis.
Using these models, researchers can evaluate the pharmacodynamics and pharmacokinetics of experimental drugs, understand tumor-host interactions, and investigate microenvironment influences on leukemia growth and survival. Xenografts also enable testing of immunotherapies, such as monoclonal antibodies and CAR-T cells, in a living system.
Challenges include ensuring the human cells engraft efficiently and recapitulate patient disease features. Advances in mouse strains lacking key immune components have improved engraftment rates and model fidelity.
By bridging the gap between cell culture and clinical trials, leukemia xenograft models provide critical data that guide drug development, dosing strategies, and combination therapy designs. They help reduce the risk of late-stage drug failure by providing early efficacy signals in a relevant biological context.
References: Altogen.com Altogenlabs.com